Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.

Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, Zanotti L, Bugatti M, Borella F, Katsaros D, Tognon G, Sartori E, Odicino F, Romualdi C, Ravaggi A.

Br J Cancer. 2019 Aug 22. doi: 10.1038/s41416-019-0553-z. [Epub ahead of print]

PMID:
31434988
2.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5829.

3.

Claudin3 is localized outside the tight junctions in human carcinomas.

Corsini M, Ravaggi A, Odicino F, Santin AD, Ravelli C, Presta M, Romani C, Mitola S.

Oncotarget. 2018 Apr 6;9(26):18446-18453. doi: 10.18632/oncotarget.24858. eCollection 2018 Apr 6.

4.

RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients.

Vezzoli M, Ravaggi A, Zanotti L, Miscioscia RA, Bignotti E, Ragnoli M, Gambino A, Ruggeri G, Calza S, Sartori E, Odicino F.

Sci Rep. 2017 Sep 5;7(1):10528. doi: 10.1038/s41598-017-11104-4.

5.

Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer.

Zanotti L, Paderno A, Piazza C, Pagan E, Bignotti E, Romani C, Bandiera E, Calza S, Del Bon F, Nicolai P, Ravaggi A.

Laryngoscope. 2017 Nov;127(11):E408-E414. doi: 10.1002/lary.26797. Epub 2017 Aug 7.

PMID:
28782189
6.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

7.

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.

Zanotti L, Romani C, Tassone L, Todeschini P, Tassi RA, Bandiera E, Damia G, Ricci F, Ardighieri L, Calza S, Marchini S, Beltrame L, Tognon G, D'Incalci M, Pecorelli S, Sartori E, Odicino F, Ravaggi A, Bignotti E.

BMC Cancer. 2017 May 25;17(1):366. doi: 10.1186/s12885-017-3334-1.

8.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

9.

Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.

Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, Tognon G, Gambino A, Calura E, Caratti G, Martini P, Beltrame L, Maragoni L, Gallo D, Odicino FE, Sartori E, Scambia G, Negrini M, Ravaggi A, D'Incalci M, Marchini S, Bignotti E, Romualdi C.

Cancer Lett. 2017 Mar 1;388:320-327. doi: 10.1016/j.canlet.2016.12.017. Epub 2016 Dec 22.

PMID:
28017893
10.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26.

11.

lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.

Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, Odicino FE, Sartori E, Perego P, Katsaros D, Craparotta I, Chiorino G, Cagnin S, Mannarino L, Ceppi L, Mangioni C, Ghimenti C, D'Incalci M, Marchini S, Romualdi C.

Clin Cancer Res. 2017 May 1;23(9):2356-2366. doi: 10.1158/1078-0432.CCR-16-1402. Epub 2016 Nov 8.

12.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

13.

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.

Bandiera E, Todeschini P, Romani C, Zanotti L, Erba E, Colmegna B, Bignotti E, Santin AD, Sartori E, Odicino FE, Pecorelli S, Tassi RA, Ravaggi A.

Oncol Lett. 2016 Oct;12(4):2493-2500. Epub 2016 Aug 16.

14.

Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.

Bignotti E, Calza S, Tassi RA, Zanotti L, Bandiera E, Sartori E, Odicino FE, Ravaggi A, Todeschini P, Romani C.

J Cell Mol Med. 2016 Dec;20(12):2341-2348. doi: 10.1111/jcmm.12927. Epub 2016 Jul 15.

15.

A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.

Calura E, Paracchini L, Fruscio R, DiFeo A, Ravaggi A, Peronne J, Martini P, Sales G, Beltrame L, Bignotti E, Tognon G, Milani R, Clivio L, Dell'Anna T, Cattoretti G, Katsaros D, Sartori E, Mangioni C, Ardighieri L, D'Incalci M, Marchini S, Romualdi C.

Ann Oncol. 2016 Aug;27(8):1511-9. doi: 10.1093/annonc/mdw210. Epub 2016 May 18.

PMID:
27194815
16.

Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study.

Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R.

Eur J Cancer Prev. 2017 Jul;26(4):346-350. doi: 10.1097/CEJ.0000000000000259.

PMID:
27116243
17.

Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Ardighieri L, Mori L, Conzadori S, Bugatti M, Falchetti M, Donzelli CM, Ravaggi A, Odicino FE, Facchetti F.

Virchows Arch. 2016 Jul;469(1):61-9. doi: 10.1007/s00428-016-1933-x. Epub 2016 Apr 8.

PMID:
27059324
18.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.

Gynecol Oncol. 2016 May;141(2):303-311. doi: 10.1016/j.ygyno.2016.01.016. Epub 2016 Jan 19.

PMID:
26801941
19.

Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy.

Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, Macuks R.

Int J Gynecol Cancer. 2016 Jan;26(1):52-5. doi: 10.1097/IGC.0000000000000579.

PMID:
26512790
20.

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery.

Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S.

Oncotarget. 2015 Oct 27;6(33):34617-28. doi: 10.18632/oncotarget.5315.

21.

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.

Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, Fotia V, Romualdi C, Martini P, Noris M, Paracchini L, Craparotta I, Petrillo M, Milani R, Perego P, Ravaggi A, Zambelli A, Ronchetti E, D'Incalci M, Marchini S.

Ann Oncol. 2015 Jul;26(7):1363-71. doi: 10.1093/annonc/mdv164. Epub 2015 Apr 6.

PMID:
25846551
22.

Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues.

Romani C, Calza S, Todeschini P, Tassi RA, Zanotti L, Bandiera E, Sartori E, Pecorelli S, Ravaggi A, Santin AD, Bignotti E.

PLoS One. 2014 Dec 4;9(12):e113781. doi: 10.1371/journal.pone.0113781. eCollection 2014.

23.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
24.

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2013 Sep;51(9):1815-24. doi: 10.1515/cclm-2013-0151.

PMID:
24013103
25.

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD.

J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.

26.

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD.

Br J Cancer. 2013 Jul 23;109(2):462-71. doi: 10.1038/bjc.2013.315. Epub 2013 Jun 27.

27.

MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.

Calura E, Fruscio R, Paracchini L, Bignotti E, Ravaggi A, Martini P, Sales G, Beltrame L, Clivio L, Ceppi L, Di Marino M, Fuso Nerini I, Zanotti L, Cavalieri D, Cattoretti G, Perego P, Milani R, Katsaros D, Tognon G, Sartori E, Pecorelli S, Mangioni C, D'Incalci M, Romualdi C, Marchini S.

Clin Cancer Res. 2013 Aug 1;19(15):4114-23. doi: 10.1158/1078-0432.CCR-13-0360. Epub 2013 Jun 13.

28.

Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10.

PMID:
23583215
29.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

30.

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.

Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD.

BMC Clin Pathol. 2012 Nov 14;12:22. doi: 10.1186/1472-6890-12-22.

31.

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.

Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, Tognon G, Ragnoli M, Romani C, Tassi RA, Caimi L, Odicino FE, Sartori E, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2012 Dec;50(12):2189-98.

PMID:
23096757
32.

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.

Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A.

ISRN Obstet Gynecol. 2012;2012:245756. doi: 10.5402/2012/245756. Epub 2012 Jun 26.

33.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

34.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

35.

Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.

Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD.

Int J Gynecol Cancer. 2011 Dec;21(9):1613-21. doi: 10.1097/IGC.0b013e318228f6da.

36.

HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, Bignotti E, Tassi RA, Tognon G, Galli C, Caimi L, Pecorelli S.

Clin Chim Acta. 2011 Jul 15;412(15-16):1447-53. doi: 10.1016/j.cca.2011.04.028. Epub 2011 Apr 30.

PMID:
21557935
37.

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A.

Br J Cancer. 2011 Apr 26;104(9):1418-25. doi: 10.1038/bjc.2011.109. Epub 2011 Apr 5.

38.

Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.

Fredolini C, Meani F, Luchini A, Zhou W, Russo P, Ross M, Patanarut A, Tamburro D, Gambara G, Ornstein D, Odicino F, Ragnoli M, Ravaggi A, Novelli F, Collura D, D'Urso L, Muto G, Belluco C, Pecorelli S, Liotta L, Petricoin EF 3rd.

AAPS J. 2010 Dec;12(4):504-18. doi: 10.1208/s12248-010-9211-3. Epub 2010 Jun 12.

39.

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD.

Eur J Cancer. 2010 Mar;46(5):944-53. doi: 10.1016/j.ejca.2009.12.019. Epub 2010 Jan 8.

PMID:
20060709
40.

Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

Wei BR, Hoover SB, Ross MM, Zhou W, Meani F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quiñones OA, Belluco C, Martella L, Campagnutta E, Ravaggi A, Dai RM, Goldsmith PK, Woolard KD, Pecorelli S, Liotta LA, Petricoin EF, Simpson RM.

PLoS One. 2009 Oct 30;4(10):e7670. doi: 10.1371/journal.pone.0007670.

41.

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.

Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A.

Int J Gynecol Cancer. 2009 Aug;19(6):1015-21. doi: 10.1111/IGC.0b013e3181ab597f.

PMID:
19820362
42.

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD.

BMC Cancer. 2009 Jul 27;9:253. doi: 10.1186/1471-2407-9-253.

43.

Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas.

Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9. doi: 10.1016/j.ajog.2009.02.010. Epub 2009 May 8.

44.

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas.

Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD.

Br J Cancer. 2008 Sep 2;99(5):768-73. doi: 10.1038/sj.bjc.6604546.

45.

Claudin-7 expression in human epithelial ovarian cancer.

Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1262-71. doi: 10.1111/j.1525-1438.2008.01194.x. Epub 2008 Feb 19.

PMID:
18298564
46.

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ.

J Virol. 2008 Feb;82(4):1968-79. Epub 2007 Dec 5.

47.

Mammaglobin B expression in human endometrial cancer.

Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. Epub 2007 Nov 16.

PMID:
18021217
48.

Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11.

PMID:
17346539
49.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85. Epub 2007 Mar 6.

PMID:
17343903
50.

Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients.

Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S.

Arch Virol. 2006 Oct;151(10):1899-916. Epub 2006 May 29.

PMID:
16732494

Supplemental Content

Loading ...
Support Center